Yuan F - Search Results

1

Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody.

Lu X, Zhan X, Xia G, Wang F, Lv M, Liu R, Liu Y, Zi C, Li G, Wang R, Li J, Yuan F, Jia D. Lu X, et al. Among authors: yuan f. Mol Pharm. 2025 Jan 6;22(1):284-294. doi: 10.1021/acs.molpharmaceut.4c00891. Epub 2024 Dec 2. Mol Pharm. 2025. PMID: 39620978

2

Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models.

Jia D, Yang Y, Yuan F, Fan Q, Wang F, Huang Y, Song H, Hu P, Wang R, Li G, Liu R, Li J. Jia D, et al. Among authors: yuan f. Int J Pharm. 2020 Aug 30;586:119541. doi: 10.1016/j.ijpharm.2020.119541. Epub 2020 Jun 13. Int J Pharm. 2020. PMID: 32544521

3

Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors.

Jia D, Wang F, Lu Y, Hu P, Wang R, Li G, Liu R, Li J, Liu H, Fan Q, Yuan F. Jia D, et al. Among authors: yuan f. Int J Pharm. 2022 May 25;620:121746. doi: 10.1016/j.ijpharm.2022.121746. Epub 2022 Apr 12. Int J Pharm. 2022. PMID: 35427745

4

Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors.

Chang R, Fu R, Huang Y, Zhang J, Feng C, Wang R, Yan H, Li G, Chu X, Yuan F, Jia D, Li J. Chang R, et al. Among authors: yuan f. Mol Pharm. 2023 Jun 5;20(6):2864-2875. doi: 10.1021/acs.molpharmaceut.2c01013. Epub 2023 May 3. Mol Pharm. 2023. PMID: 37134184

5

Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models.

Jia D, Wang F, Yang Y, Hu P, Song H, Lu Y, Wang R, Li G, Liu R, Li J, Yuan F. Jia D, et al. Among authors: yuan f. J Pharm Sci. 2022 Feb;111(2):450-457. doi: 10.1016/j.xphs.2021.09.018. Epub 2021 Sep 20. J Pharm Sci. 2022. PMID: 34547305

6

Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors.

Liu H, Jia D, Yuan F, Wang F, Wei D, Tang X, Tian B, Zheng S, Sun R, Shi J, Fan Q. Liu H, et al. Among authors: yuan f. Int J Pharm. 2022 Apr 5;617:121609. doi: 10.1016/j.ijpharm.2022.121609. Epub 2022 Feb 22. Int J Pharm. 2022. PMID: 35217073

7

ICG-Dimeric Her2-Specific Affibody Conjugates for Tumor Imaging and Photothermal Therapy for Her2-Positive Tumors.

Jia D, Liu H, Zheng S, Yuan D, Sun R, Wang F, Li Y, Li H, Yuan F, Fan Q, Zhao Z. Jia D, et al. Among authors: yuan d, yuan f. Mol Pharm. 2023 Jan 2;20(1):427-437. doi: 10.1021/acs.molpharmaceut.2c00708. Epub 2022 Oct 31. Mol Pharm. 2023. PMID: 36315025

8

Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.

Jia D, Lu Y, Lv M, Wang F, Lu X, Zhu W, Wei J, Guo W, Liu R, Li G, Wang R, Li J, Yuan F. Jia D, et al. Among authors: yuan f. J Control Release. 2023 Aug;360:858-871. doi: 10.1016/j.jconrel.2023.07.030. Epub 2023 Jul 26. J Control Release. 2023. PMID: 37473808

9

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy.

Wang H, Jia D, Yuan D, Yin X, Yuan F, Wang F, Shi W, Li H, Zhu LM, Fan Q. Wang H, et al. Among authors: yuan d, yuan f. J Nanobiotechnology. 2021 May 13;19(1):138. doi: 10.1186/s12951-021-00885-6. J Nanobiotechnology. 2021. PMID: 33985511 Free PMC article.

10

SLAMF7 Promotes Foam Cell Formation of Macrophage by Suppressing NR4A1 Expression During Carotid Atherosclerosis.

Yuan F, Wei J, Cheng Y, Wang F, Gu M, Li Y, Zhao X, Sun H, Ban R, Zhou J, Xia Z. Yuan F, et al. Inflammation. 2024 Apr;47(2):530-542. doi: 10.1007/s10753-023-01926-y. Epub 2023 Nov 16. Inflammation. 2024. PMID: 37971565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,066 results

Search Page

Filters